



NOVUSON is revolutionizing surgical energy devices with the world's first low-heat, smoke-free, precision vessel sealing platform.

Novuson is an innovative medical device company, founded 2014 based in Bothell, WA, developing the world's first Direct Therapeutic Ultrasound (DTU™) surgical instrument platform for minimally invasive, robotic and endoscopic surgeries. Novuson's launch product (3mm MiniLS) is essential for Vessel Sealing/Dividing in Gynecological, Urological, Bariatric, Pediatric, Trauma, and other surgical specialties. Novuson holds 18 US and international patents. The first product launch of the platform will be first-in-class 3mm Mini-Laparoscopic Sealer/Divider.



UNMET NEED IN THE \$10.2Bn SURGICAL DEVICE MARKET

Current surgical energy devices burn and char the patient, resulting in plumes of smoke being generated. This obscures the surgeon's vision and leads to unintentional injuries. Studies revealed 33% of surgeries have complications. 49% of these surgical complications were avoidable, 77% of which were due to technical errors (Healy *et al*). Results such as these are driving the surgical market towards smaller, more precise, and robotic systems that don't generate smoke or burn the patient.

ADVANCED TECHNOLOGY

Novuson's patented DTU technology is the first substantive innovation in 25+ years for vessel sealing / dividing, soft tissue ablation / hemostasis (bleeding control) in surgical and trauma applications. The Novuson DTU technology value proposition has been validated in over 1000 bench and animal studies. DTU operates at significantly lower temperatures than the current Harmonic and Radio Frequency devices; thus, tissue is not burnt or charred, resulting in more precise, safer, smoke free surgeries as compared to those technologies. DTU reduced thermal spread by approximately 75% in pre-clinical studies

INVESTMENT OPPORTUNITY


All-in outside capital is ~\$10M, of which, ~\$7.0M is equity and \$3.2M is non-dilutive NIH Grant Funding. We have received strategic investments and are in discussions for further strategic investments. Currently we have a \$3.0M preferred equity round open to: 1) Finalize contract manufacture (Q2, 2026) Submit/Receive regulatory 510k clearance (Q3 2026), 3) Product Launch (3mm MiniLS) in Ambulatory Surgical Centers (Q4 2026). Next Raise \$10M in subsequent rounds to exit via acquisition with full portfolio of products.



Contact with Inquiries:

Stuart B. Mitchell, CEO & Founder
425.238.6227, sbmitchell@novuson.com

www.novuson.com



DIRECT THERAPEUTIC ULTRASOUND (DTU)
Applies Energy from the Inside, Out

NOVUSON LEADERSHIP

Stuart B Mitchell, PhD
CEO, Founder, Inventor

Over 20 years' experience in biomedical instrumentation, 12 years in acoustic device and 15 years in tissue response to stimuli. Inventor of Novuson's technology, conceptualized the market space, and developed the business strategy. Managed multi-million-dollar corporations/projects for 30 years. Received IDE from US FDA for HIFU treatment for pancreatic cancer. Started ACCES with Jean Maixner, grew to a multi-location practice with 70% CAGR, successful exit via acquisition with significant ROI. PI of 3 awarded NIH small business grants totaling 3.25M in Non-Dilutive Funding for Novuson.

Marco Daoura, MS BioE
EVP of Program and Product Management

Over 20 years' of experience in the healthcare industry from Philips Healthcare to Fujifilm Medical Systems, and UltraLinq Healthcare. Mr. Daoura has been responsible for a number of successful life sciences product launches, where he optimized development and commercialization strategies around the five healthcare verticals.

Mary Waiss,
Chief Commercialization Officer

Senior Executive (CEO, Managing Director, Board Member): Experienced Leader & Entrepreneur in the Biomedical, Life Science and Healthcare Innovation & Technology Space

Mart Pearson
Business Development and Strategy
34 years new technology introduction in surgery. Global commercialization for early-stage companies. Product positioning and marketing.

Derek Khorsand, MD
Chief Medical Officer
University of Washington Department of Radiology

NOVUSON